With new phase 3 data in hand, Boehringer Ingelheim is preparing to file for approval of nerandomilast, a would-be successor to its blockbuster idiopathic pulmonary fibrosis (IPF) therapy Ofev.

Boehringer Ingelheim has started a registration trial of its experimental therapy brigimadlin as a treatment for dedifferentiated liposarcoma (DDLPS), a rare cancer with limited treatment options.

By Noah Weiland and Rebecca Robbins Hikma said it had reduced the cash portion of the offer as Boehringer Ingelheim’s generic drugs business in the U.S. had lower-than-expected sales.

She's currently the Chief Medical Officer and Head of Medicine at Boehringer Ingelheim. Well, Dr. Hinsch Gylvin. Thanks for joining me today. That really has changed. So first and foremost ...

With 3 used Swift Challenger Sport 554 caravans available on Auto Trader, we have the best range of caravans for sale across the UK.

The heritage of Boehringer Ingelheim in developing medicines for respiratory diseases spans almost 100 years. Within the respiratory disease area, innovative treatments for chronic obstructive ...

Boehringer Ingelheim is supporting this transformation by partnering with groups working across psychiatric R&D, from small molecules to digital therapeutics. Recognizing the potential to improve ...

Welcome to this stunning 1999 Henley Properties built home, a luxurious 4 bedroom, two-story oasis nestled on a generous 5,008m² block. This exceptional haven blends modern living with natural ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...